This year BMC Cancer is celebrating its 20th Anniversary. Since launching in 2001 we are proud to have become a leading Open Access journal in the oncology field, considering all areas of cancer research from cancer cell biology to epidemiology to cancer therapeutics and much more. We're looking back at our achievements and highlighting some of the most influential research published in the journal over the past two decades.
Celebrating 20 Years of BMC Cancer
New in BMC Cancer
Support and Guidance
How do physicians and nurses perceive the benefits of clinical trial participation compared with standard care? Is it justified to claim that clinical trial participation improves outcomes for cancer patients? Zandra Nielsen et al. present their latest findings of a mixed-methods study in Scandinavia.
Featured video: Microparticles, breast cancer's secret weapon?
Aims and Scope
BMC Cancer is an open access, peer-reviewed journal that considers articles on all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers. The journal welcomes submissions in broad areas of cancer research including molecular and cellular biology, genetics, epidemiology, and clinical trials.
Peer Review Taxonomy
This journal is participating in a pilot of NISO/STM's Working Group on Peer Review Taxonomy, to identify and standardize definitions and terminology in peer review practices in order to make the peer review process for articles and journals more transparent. Further information on the pilot is available here.
The following summary describes the peer review process for this journal:
- Identity transparency: Single anonymized
- Reviewer interacts with: Editor
- Review information published: Review reports. Reviewer Identities reviewer opt in. Author/reviewer communication
We welcome your feedback on this Peer Review Taxonomy Pilot. Please can you take the time to complete this short survey.
The Editors of BMC Cancer and BMC Medicine invite of submissions to our ‘Targeted Therapy’ cross journal collection. Guest edited by Prof. Min Li (University of Oklahoma Health Sciences Center, USA) and Dr. Yanis Boumber (The Northwestern University, USA).
The Editors of BMC Cancer, BMC Microbiology and Microbiome invite of submissions to our ‘Microbiome and Cancer’ cross journal collection. Guest edited by Prof. Christopher Staley, Dr. Jacques Ravel and Dr. Sean Devlin.
The Collection is open for submissions until 31st December 2021.
BMC Series Focus Issues
Microbial resistance has become a major threat to human health in the 21st century. In order to provide the public with a general understanding of the situation of drug-resistant pathogens, and to alert and prevent this threat, the BMC Series Journals dedicate their first focus issue in 2022 to research on antimicrobial resistance.
For World AIDS day, the BMC Series Journals dedicate this month's focus issue to research on HIV and AIDS highlighting recent advancements in understanding the biology of the disease, the continued breakthroughs in diagnosis and treatment and also shed some light on what life with HIV is like.
Click here to view which Articles have been shared most in the last 6 months!
BMC Series Blog
19 January 2022
Follow Nobel Prize laureates James P. Allison's and Tasuku Honjo's footsteps and experience the genesis of a new field of cancer therapy. BMC Cancer Editorial Board Member Dr. Sheng Guo from Pittsburgh University takes us on an exciting journey of discovery...
Annual Journal Metrics
79 days to first decision for reviewed manuscripts only
55 days to first decision for all manuscripts
170 days from submission to acceptance
16 days from acceptance to publication
4.430 - 2-year Impact Factor
4.372 - 5-year Impact Factor
1.218 - Source Normalized Impact per Paper (SNIP)
1.358 - SCImago Journal Rank (SJR)
2,117 Altmetric Mentions